Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 353 (9167), 1843-1847
- https://doi.org/10.1016/s0140-6736(98)11467-8
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Trends in Drug-Resistant Tuberculosis in the United States, 1993-1996Published by American Medical Association (AMA) ,1997
- Noncompliance With Directly Observed Therapy for TuberculosisChest, 1997
- Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.American Journal of Respiratory and Critical Care Medicine, 1994
- The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in TuberculosisNew England Journal of Medicine, 1994
- The rpoB gene of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1994
- Effectiveness of Rifampin, Rifabutin, and Rifapentine for Preventive Therapy of Tuberculosis in MiceAmerican Review of Respiratory Disease, 1993
- Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosisTubercle and Lung Disease, 1992
- In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosisTubercle, 1987
- Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.The Journal of Antibiotics, 1981
- Evaluation of patients with advanced cancer using the karnofsky performance statusCancer, 1980